DK1682124T3 - Farmaceutiske præparater på grundlag af idazoxansalt elle4r en polymorf deraf - Google Patents

Farmaceutiske præparater på grundlag af idazoxansalt elle4r en polymorf deraf

Info

Publication number
DK1682124T3
DK1682124T3 DK04805330T DK04805330T DK1682124T3 DK 1682124 T3 DK1682124 T3 DK 1682124T3 DK 04805330 T DK04805330 T DK 04805330T DK 04805330 T DK04805330 T DK 04805330T DK 1682124 T3 DK1682124 T3 DK 1682124T3
Authority
DK
Denmark
Prior art keywords
idazoxan
salt
pharmaceutical composition
neuroleptic
exhibiting
Prior art date
Application number
DK04805330T
Other languages
Danish (da)
English (en)
Inventor
Joel Bougaret
Jean-Louis Avan
Roland Segonds
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Application granted granted Critical
Publication of DK1682124T3 publication Critical patent/DK1682124T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04805330T 2003-10-28 2004-10-28 Farmaceutiske præparater på grundlag af idazoxansalt elle4r en polymorf deraf DK1682124T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312626A FR2861299B1 (fr) 2003-10-28 2003-10-28 Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
PCT/FR2004/002773 WO2005041956A1 (fr) 2003-10-28 2004-10-28 Compositions pharmaceutiques a base de sel d’idazoxan ou l’un de ses polymorphes

Publications (1)

Publication Number Publication Date
DK1682124T3 true DK1682124T3 (da) 2008-04-28

Family

ID=34400871

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04805330T DK1682124T3 (da) 2003-10-28 2004-10-28 Farmaceutiske præparater på grundlag af idazoxansalt elle4r en polymorf deraf

Country Status (19)

Country Link
US (2) US7338970B2 (de)
EP (1) EP1682124B1 (de)
JP (1) JP5160090B2 (de)
CN (2) CN1870993B (de)
AT (1) ATE381331T1 (de)
AU (1) AU2004285316B2 (de)
BR (1) BRPI0416006B1 (de)
CA (1) CA2542752A1 (de)
CY (1) CY1107304T1 (de)
DE (1) DE602004010837T2 (de)
DK (1) DK1682124T3 (de)
ES (1) ES2297525T3 (de)
FR (1) FR2861299B1 (de)
HK (1) HK1094769A1 (de)
HR (1) HRP20080108T3 (de)
MX (1) MXPA06004717A (de)
PL (1) PL1682124T3 (de)
PT (1) PT1682124E (de)
WO (1) WO2005041956A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476307B2 (en) * 2003-10-28 2013-07-02 Pierre Fabre Medicament Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
WO2023159145A1 (en) * 2022-02-16 2023-08-24 Terran Biosciences, Inc. Deuterated idazoxan and methods of use thereof
CN117338772B (zh) * 2023-11-22 2024-04-09 徐州医科大学 一种药物组合物及其在制备用于预防和/或治疗重性抑郁障碍的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH16249A (en) * 1980-02-04 1983-08-16 Reckitt & Colmann Prod Ltd Imidazoline derivatives,its pharmaceutical composition and method of use
US4541893A (en) * 1984-05-15 1985-09-17 Advanced Micro Devices, Inc. Process for fabricating pedestal interconnections between conductive layers in an integrated circuit
FR2698789B1 (fr) 1992-12-07 1995-03-03 Pf Medicament Utilisation de l'idazoxan et ses dérivés pour la préparation d'un médicament destiné au traitement de la maladie de Parkinson et de son évolution.
US5492907A (en) * 1992-12-09 1996-02-20 The United States Of America As Represented By The Department Of Health & Human Services Antipsychotic composition and method of treatment
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
US5574059A (en) * 1995-10-27 1996-11-12 Cornell Research Foundation, Inc. Treating disorders mediated by vascular smooth muscle cell proliferation
FR2746314B1 (fr) 1996-03-25 1998-06-12 Pf Medicament Produit contenant du milnacipran et de l'idazoxan comme preparation pharmaceutique combinee
US6232215B1 (en) * 1996-09-18 2001-05-15 United Microelectronics Corp. Method for forming increased density for interconnection metallization
FR2774811B1 (fr) * 1998-02-10 2003-05-09 Sgs Thomson Microelectronics Procede de formation de lignes conductrices sur des circuits integres
FR2801786B1 (fr) * 1999-12-01 2002-03-01 Fabre Pierre Cosmetique Nouvelles compositions topiques a base d'idazoxan et de cafeine ou de ses derives solubles et leur utilisation comme amincissant et/ou dans le traitement de la cellulite

Also Published As

Publication number Publication date
CN102349873A (zh) 2012-02-15
DE602004010837D1 (de) 2008-01-31
CN102349873B (zh) 2013-09-25
EP1682124A1 (de) 2006-07-26
WO2005041956A1 (fr) 2005-05-12
US8124640B2 (en) 2012-02-28
US20080113022A1 (en) 2008-05-15
ATE381331T1 (de) 2008-01-15
US7338970B2 (en) 2008-03-04
CA2542752A1 (fr) 2005-05-12
ES2297525T3 (es) 2008-05-01
HRP20080108T3 (en) 2008-04-30
DE602004010837T2 (de) 2008-12-11
CY1107304T1 (el) 2012-11-21
FR2861299A1 (fr) 2005-04-29
JP5160090B2 (ja) 2013-03-13
FR2861299B1 (fr) 2006-01-27
AU2004285316B2 (en) 2010-08-19
HK1094769A1 (en) 2007-04-13
PL1682124T3 (pl) 2008-05-30
MXPA06004717A (es) 2006-07-05
PT1682124E (pt) 2008-03-05
CN1870993B (zh) 2012-04-04
US20050090537A1 (en) 2005-04-28
AU2004285316A1 (en) 2005-05-12
JP2007509911A (ja) 2007-04-19
EP1682124B1 (de) 2007-12-19
CN1870993A (zh) 2006-11-29
BRPI0416006B1 (pt) 2019-02-05
BRPI0416006A (pt) 2007-01-02

Similar Documents

Publication Publication Date Title
AU756468B2 (en) Combination therapy for treatment of bipolar disorders
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
NO20075641L (no) Kroman og kromenderivater og ders anvendelse
US20050233010A1 (en) Lithium combinations, and uses related thereto
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
JP2008531714A (ja) 不安障害の治療用及び／又は予防用の医薬組成物
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
RU2007132852A (ru) Продукт комбинации о-десметилвенлафаксина и базедоксифена и его применение
HRP20080108T3 (en) Pharmaceutical compositions based on idazoxan salt or one of its polymorphs
SE0104341D0 (sv) New use
CA2507002A1 (en) Solid drug for oral use
ES2193875A1 (es) Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
PE20061318A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
JP6406713B2 (ja) 低用量薬剤によるうつ病および他の疾患の処置
HRP20090569T1 (hr) Stabilni kristalni oblici bifeprunoks mesilata, oblici njihovog doziranja i postupak njihovog korištenja
JP2007516193A5 (de)
JPS63258819A (ja) ドーパミン受容体アゴニストの新規用途
WO1999061027A1 (en) Combination therapy for treatment of refractory depression
EP1784173A4 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat-derivaten
CA2488138A1 (en) Treatment for depression and anxiety by the combination of a pde iv inhibitor and an antidepressant or an anxiolytic agent
GEP20074225B (en) Use of carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
DE60215525D1 (de) Kombination aus quetiapin und zolmitriptan
TW200513462A (en) Stable polymorph of bifeprunox mesilate (7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)